166 related articles for article (PubMed ID: 34949286)
1. The implications of the use of cannabidiol-related products in a safety-sensitive drug testing environment: A medical-legal perspective.
Jooste J; Laurens JB; Jordaan M; Marais AAS; Curlewis LG
S Afr Med J; 2021 Oct; 111(10):942-945. PubMed ID: 34949286
[TBL] [Abstract][Full Text] [Related]
2. Cannabidiol and tetrahydrocannabinol concentrations in commercially available CBD E-liquids in Switzerland.
Grafinger KE; Krönert S; Broillet A; Weinmann W
Forensic Sci Int; 2020 May; 310():110261. PubMed ID: 32229319
[TBL] [Abstract][Full Text] [Related]
3. Content versus Label Claims in Cannabidiol (CBD)-Containing Products Obtained from Commercial Outlets in the State of Mississippi.
Gurley BJ; Murphy TP; Gul W; Walker LA; ElSohly M
J Diet Suppl; 2020; 17(5):599-607. PubMed ID: 32431186
[TBL] [Abstract][Full Text] [Related]
4. Origin of Δ
Citti C; Russo F; Linciano P; Strallhofer SS; Tolomeo F; Forni F; Vandelli MA; Gigli G; Cannazza G
Cannabis Cannabinoid Res; 2021; 6(1):28-39. PubMed ID: 33614950
[No Abstract] [Full Text] [Related]
5. A Critical Review of the Role of the Cannabinoid Compounds Δ
Jones É; Vlachou S
Molecules; 2020 Oct; 25(21):. PubMed ID: 33113776
[TBL] [Abstract][Full Text] [Related]
6. A randomised controlled trial of vaporised Δ
Solowij N; Broyd S; Greenwood LM; van Hell H; Martelozzo D; Rueb K; Todd J; Liu Z; Galettis P; Martin J; Murray R; Jones A; Michie PT; Croft R
Eur Arch Psychiatry Clin Neurosci; 2019 Feb; 269(1):17-35. PubMed ID: 30661105
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of recombinant human T-type calcium channels by Delta9-tetrahydrocannabinol and cannabidiol.
Ross HR; Napier I; Connor M
J Biol Chem; 2008 Jun; 283(23):16124-34. PubMed ID: 18390906
[TBL] [Abstract][Full Text] [Related]
8. A crowdsourcing survey study on the subjective effects of delta-8-tetrahydrocannabinol relative to delta-9-tetrahydrocannabinol and cannabidiol.
Bergeria CL; Strickland JC; Spindle TR; Kalaba M; Satyavolu PU; Feldner M; Vandrey R; Bonn-Miller M; Peters EN; Weerts E
Exp Clin Psychopharmacol; 2023 Apr; 31(2):312-317. PubMed ID: 35467921
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics and pharmacodynamics of five distinct commercially available hemp-derived topical cannabidiol products.
Zamarripa CA; Tilton HE; Lin S; Cone EJ; Winecker RE; Flegel RR; Kuntz D; Beals M; Jacques M; Clark M; Welsh ER; Wagner L; Bonn-Miller MO; Vandrey R; Spindle TR
J Anal Toxicol; 2024 Mar; 48(2):81-98. PubMed ID: 38217086
[TBL] [Abstract][Full Text] [Related]
10. Cannabinoid Content and Label Accuracy of Hemp-Derived Topical Products Available Online and at National Retail Stores.
Spindle TR; Sholler DJ; Cone EJ; Murphy TP; ElSohly M; Winecker RE; Flegel RR; Bonn-Miller MO; Vandrey R
JAMA Netw Open; 2022 Jul; 5(7):e2223019. PubMed ID: 35857320
[TBL] [Abstract][Full Text] [Related]
11. Comment on Lachenmeier
Kruse D; Beitzke B
F1000Res; 2020; 9():900. PubMed ID: 32864108
[TBL] [Abstract][Full Text] [Related]
12. THC and CBD concentrations in blood, oral fluid and urine following a single and repeated administration of "light cannabis".
Pacifici R; Pichini S; Pellegrini M; Rotolo MC; Giorgetti R; Tagliabracci A; Busardò FP; Huestis MA
Clin Chem Lab Med; 2020 Apr; 58(5):682-689. PubMed ID: 30956228
[TBL] [Abstract][Full Text] [Related]
13. Industrial, CBD, and Wild Hemp: How Different Are Their Essential Oil Profile and Antimicrobial Activity?
Zheljazkov VD; Sikora V; Dincheva I; Kačániová M; Astatkie T; Semerdjieva IB; Latkovic D
Molecules; 2020 Oct; 25(20):. PubMed ID: 33053634
[TBL] [Abstract][Full Text] [Related]
14. Cannabidiol and Δ8-Tetrahydrocannabinol: Cannabinoids of Rising Interest and Concern.
White RM
Forensic Sci Rev; 2023 Jan; 35(1):27-45. PubMed ID: 36575371
[TBL] [Abstract][Full Text] [Related]
15. Simultaneous determination of cannabidiol, cannabinol, and delta9-tetrahydrocannabinol in human hair by gas chromatography-mass spectrometry.
Kim JY; Suh SI; In MK; Paeng KJ; Chung BC
Arch Pharm Res; 2005 Sep; 28(9):1086-91. PubMed ID: 16212242
[TBL] [Abstract][Full Text] [Related]
16. Effect of Cannabidiol and Δ9-Tetrahydrocannabinol on Driving Performance: A Randomized Clinical Trial.
Arkell TR; Vinckenbosch F; Kevin RC; Theunissen EL; McGregor IS; Ramaekers JG
JAMA; 2020 Dec; 324(21):2177-2186. PubMed ID: 33258890
[TBL] [Abstract][Full Text] [Related]
17. Cannabidiol (CBD) product contamination: Quantitative analysis of Δ
Johnson E; Kilgore M; Babalonis S
Drug Alcohol Depend; 2022 Aug; 237():109522. PubMed ID: 35690015
[TBL] [Abstract][Full Text] [Related]
18. Probing the antioxidant activity of Δ
Hacke ACM; Lima D; de Costa F; Deshmukh K; Li N; Chow AM; Marques JA; Pereira RP; Kerman K
Analyst; 2019 Aug; 144(16):4952-4961. PubMed ID: 31318364
[TBL] [Abstract][Full Text] [Related]
19. Distinct effects of {delta}9-tetrahydrocannabinol and cannabidiol on neural activation during emotional processing.
Fusar-Poli P; Crippa JA; Bhattacharyya S; Borgwardt SJ; Allen P; Martin-Santos R; Seal M; Surguladze SA; O'Carrol C; Atakan Z; Zuardi AW; McGuire PK
Arch Gen Psychiatry; 2009 Jan; 66(1):95-105. PubMed ID: 19124693
[TBL] [Abstract][Full Text] [Related]
20. Analysis of Cannabidiol, Δ
ElSohly MA; Murphy TP; Khan I; Walker LW; Gul W
Med Cannabis Cannabinoids; 2020 Aug; 3(1):1-13. PubMed ID: 34676337
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
